Research ExplorerPublicationsSpeichelgangkarzinome

Speichelgangkarzinome

Standard

Speichelgangkarzinome : Salivary duct carcinoma. / Hungermann, D; Roeser, K; Buerger, H; Jäkel, T; Löning, T; Herbst, H.

In: PATHOLOGE, Vol. 26, No. 5, 09.2005, p. 353-8.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Hungermann, D, Roeser, K, Buerger, H, Jäkel, T, Löning, T & Herbst, H 2005, 'Speichelgangkarzinome: Salivary duct carcinoma', PATHOLOGE, vol. 26, no. 5, pp. 353-8. https://doi.org/10.1007/s00292-005-0775-0

APA

Hungermann, D., Roeser, K., Buerger, H., Jäkel, T., Löning, T., & Herbst, H. (2005). Speichelgangkarzinome: Salivary duct carcinoma. PATHOLOGE, 26(5), 353-8. https://doi.org/10.1007/s00292-005-0775-0

Vancouver

Hungermann D, Roeser K, Buerger H, Jäkel T, Löning T, Herbst H. Speichelgangkarzinome: Salivary duct carcinoma. PATHOLOGE. 2005 Sep;26(5):353-8. https://doi.org/10.1007/s00292-005-0775-0

Bibtex

@article{019a88feb67a410e9c8ea35d0e413960,
title = "Speichelgangkarzinome: Salivary duct carcinoma",
abstract = "This tutorial focuses on salivary duct carcinoma (SDC), a rare, high grade neoplasm mainly of major salivary glands. The clinical course of these tumors is characterised by extended local disease, early distant metastasis, and poor outcome. The morphology of SDC is reminiscent of breast ductal carcinomas and may occasionally cause diagnostic problems. In spite of mimicry with ductal carcinoma in situ of the breast and an in situ component, that is evident in most tumors by immunohistology with antibodies directed against high molecular weight cytokeratins (Ck), SDC is always an invasive carcinoma. By immunohistology, most tumors show reactivity with antibodies directed against Ck 7, Ck 8/18 and Ck 19 whereas a morphologically indistinguishable subgroup expresses Ck 5/6 in tumor cells in addition to residual basal epithelia. Carcinoembryonic antigen, GCDFP-15 and androgen receptor are other helpful markers in routine diagnosis of SDC. Prostate-specific antigen is detectable in some cases. Abnormal p53 expression seems to indicate an adverse prognosis. Expression of c-erbB2, the over-expression of which is associated with a poor prognosis, may form the basis for a targeted therapeutic approach for selected cases of SDC.",
keywords = "Biomarkers, Tumor, Breast Neoplasms, Carcinoma, Ductal, Humans, Male, Prognosis, Salivary Ducts, Salivary Gland Neoplasms, English Abstract, Journal Article, Research Support, Non-U.S. Gov't, Review",
author = "D Hungermann and K Roeser and H Buerger and T J{\"a}kel and T L{\"o}ning and H Herbst",
year = "2005",
month = sep,
doi = "10.1007/s00292-005-0775-0",
language = "Deutsch",
volume = "26",
pages = "353--8",
journal = "PATHOLOGE",
issn = "0172-8113",
publisher = "Springer",
number = "5",

}

RIS

TY - JOUR

T1 - Speichelgangkarzinome

T2 - Salivary duct carcinoma

AU - Hungermann, D

AU - Roeser, K

AU - Buerger, H

AU - Jäkel, T

AU - Löning, T

AU - Herbst, H

PY - 2005/9

Y1 - 2005/9

N2 - This tutorial focuses on salivary duct carcinoma (SDC), a rare, high grade neoplasm mainly of major salivary glands. The clinical course of these tumors is characterised by extended local disease, early distant metastasis, and poor outcome. The morphology of SDC is reminiscent of breast ductal carcinomas and may occasionally cause diagnostic problems. In spite of mimicry with ductal carcinoma in situ of the breast and an in situ component, that is evident in most tumors by immunohistology with antibodies directed against high molecular weight cytokeratins (Ck), SDC is always an invasive carcinoma. By immunohistology, most tumors show reactivity with antibodies directed against Ck 7, Ck 8/18 and Ck 19 whereas a morphologically indistinguishable subgroup expresses Ck 5/6 in tumor cells in addition to residual basal epithelia. Carcinoembryonic antigen, GCDFP-15 and androgen receptor are other helpful markers in routine diagnosis of SDC. Prostate-specific antigen is detectable in some cases. Abnormal p53 expression seems to indicate an adverse prognosis. Expression of c-erbB2, the over-expression of which is associated with a poor prognosis, may form the basis for a targeted therapeutic approach for selected cases of SDC.

AB - This tutorial focuses on salivary duct carcinoma (SDC), a rare, high grade neoplasm mainly of major salivary glands. The clinical course of these tumors is characterised by extended local disease, early distant metastasis, and poor outcome. The morphology of SDC is reminiscent of breast ductal carcinomas and may occasionally cause diagnostic problems. In spite of mimicry with ductal carcinoma in situ of the breast and an in situ component, that is evident in most tumors by immunohistology with antibodies directed against high molecular weight cytokeratins (Ck), SDC is always an invasive carcinoma. By immunohistology, most tumors show reactivity with antibodies directed against Ck 7, Ck 8/18 and Ck 19 whereas a morphologically indistinguishable subgroup expresses Ck 5/6 in tumor cells in addition to residual basal epithelia. Carcinoembryonic antigen, GCDFP-15 and androgen receptor are other helpful markers in routine diagnosis of SDC. Prostate-specific antigen is detectable in some cases. Abnormal p53 expression seems to indicate an adverse prognosis. Expression of c-erbB2, the over-expression of which is associated with a poor prognosis, may form the basis for a targeted therapeutic approach for selected cases of SDC.

KW - Biomarkers, Tumor

KW - Breast Neoplasms

KW - Carcinoma, Ductal

KW - Humans

KW - Male

KW - Prognosis

KW - Salivary Ducts

KW - Salivary Gland Neoplasms

KW - English Abstract

KW - Journal Article

KW - Research Support, Non-U.S. Gov't

KW - Review

U2 - 10.1007/s00292-005-0775-0

DO - 10.1007/s00292-005-0775-0

M3 - SCORING: Zeitschriftenaufsatz

C2 - 16041504

VL - 26

SP - 353

EP - 358

JO - PATHOLOGE

JF - PATHOLOGE

SN - 0172-8113

IS - 5

ER -